TORONTO (Reuters) - The Toronto Stock Exchange's main index took a bullish bounce yesterday as strong results from Manulife Financial and a drawdown in US crude oil stockpiles lifted financial and energy issues.

The S&P/TSX composite index logged its biggest percentage jump since January, up 197.62 points, or 1.5 percent, at 13,758.19. The index gained as much as two percent before easing later in the session.

"We had a pretty severe decline in terms of the rapidity of it, and we're seeing a bounce-back similar to the US market albeit deferred by a day or two," said Paul Hand, managing director at RBC Capital Markets.

"The TSX index is now heavily concentrated in financial services and energy, so ... our big-cap stocks really drive the index."

Financials gained for a second day, up 2.1 percent, following the lead of Manulife Financial , which beat expectations with a 15 percent jump in quarterly profit.

Manulife was up C$1.10, or 2.5 percent, at C$40.75. Financial issues represented most of the day's biggest net gainers, with Toronto-Dominion up C$1.72, or 2.5 percent, at C$70.75.

Financials have been battered since mid-July, and may be getting a boost from the US Federal Reserve's suggestion Tuesday that it saw economic growth ahead despite the global crisis in credit markets.

Energy stocks, which like financials account for about 30 percent of the overall index, rebounded after two losing days. The sector advanced 1.3 percent after data showed a significant draw in US crude oil and fuel stocks.

Canadian Natural Resources climbed C$2.31, or 3.3 percent, to C$72.22. Suncor Energy was up C$2.66, or 2.8 percent, at C$96.47.

Adding to the index's buoyancy Wednesday, the materials, industrials and consumer staples sectors each marched ahead more than 1 percent.

Goldcorp climbed C$1.13, or nearly 4.4 percent, to C$27.12 as bullion prices approached a two-week high on the back of a declining US dollar.

Elsewhere, Biovail Corp. was down C$1.22, or 6.2 percent, at C$18.43 after Canada's biggest publicly traded drugmaker reported a lower second-quarter profit.